Search documented disagreements and product cautions across the local library. Compare complete source versions on the drug page before choosing a regimen.
Search medication names and documented issues only. Do not enter patient information. This directory submits search filters to the server; the within-drug text finder remains a separate local feature.
A difference is not always a contradiction
Compare indication, formulation, route, population, renal method, dialysis conditions and source date. A safety update or source-quality failure is not an alternative dose. These notes are not independent clinical approval, and sources are not ranked or averaged.
Renal cautions are not interchangeable release-form schedules
SR and XL renal excerpts both recommend considering a lower dose and/or frequency, but do not provide a complete numeric renal schedule. Their release forms and ordinary administration schedules remain separate.
What to reconcile
Open the correct release-form record. Do not invent a shared renal interval or transfer a single-dose limit from another formulation.
1 source identities and dates
GlobalRPh RX List - Wellbutrin XL
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Adult product-specific renal information; not a complete prescribing regimen.
Fixed 450 mg tablet is unsuitable for a lower renal regimen
FORFIVO XL is not recommended in renal impairment because it lacks a lower strength. Other bupropion release forms must retain their own instructions.
What to reconcile
Choose an appropriate actual formulation; do not transform this fixed-dose product into a renal taper or split-dose algorithm.
1 source identities and dates
GlobalRPh RX List - FORFIVO XL
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. FORFIVO XL fixed 450 mg extended-release tablet; not other bupropion strengths or release forms.
The numeric every-other-day maximum is hepatic, not renal
The RX renal paragraph gives a qualitative reduction instruction, while the adjacent hepatic paragraph gives a numeric maximum. The repeated page sections also carry different revision dates.
What to reconcile
Do not promote the hepatic schedule into an evidence-based renal table. Reconcile the current exact smoking-cessation product label and monitor adverse effects.
1 source identities and dates
GlobalRPh RX List - ZYBAN
GlobalRPh-hosted RX List | Source revision: Mixed page sections marked June 2016 and July 2019 ZYBAN oral sustained-release smoking-cessation product; not a substituted XL regimen.
The renal contraindication is tied to indexed pediatric eGFR versus adult CrCl.
What to reconcile
Check the appropriate measure and mineral-metabolism exclusions before treatment.
1 source identities and dates
GlobalRPh RX List - CRYSVITA
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. CRYSVITA SC for the labeled hypophosphatemic disorders. Mineral metabolism and age-specific renal definitions govern eligibility.
A small renal PK study does not clear fibrotic complications
Unchanged PK in a small renal study does not establish dialysis dosing or exclude retroperitoneal fibrosis.
What to reconcile
Investigate new obstructive urinary findings or renal insufficiency rather than assuming they are an adjustment problem.
1 source identities and dates
GlobalRPh RX List - DOSTINEX
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. DOSTINEX oral treatment for hyperprolactinemic disorders; selected renal PK only.
Prevention and combination HIV treatment have different renal wording
APRETUDE and CABENUVA are not interchangeable products. HIV testing remains essential before each APRETUDE injection.
What to reconcile
Confirm the product, indication and acute-infection testing. Do not infer a dialysis supplement from protein binding.
2 source identities and dates
GlobalRPh RX List - APRETUDE
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. APRETUDE long-acting intramuscular cabotegravir for HIV-1 PrEP; not CABENUVA HIV treatment.
DailyMed / ViiV Healthcare Company | Source revision: Source revision date not established in selected retrieval. APRETUDE long-acting intramuscular cabotegravir for HIV-1 PrEP; not CABENUVA HIV treatment.
Retain the increased-monitoring instruction in severe renal disease
CABENUVA specifies additional adverse-effect monitoring in severe impairment and ESRD. The RX retrieval failed; this addition is official-label content.
What to reconcile
Confirm HIV-treatment eligibility and injection schedule; do not replace this instruction with APRETUDE wording.
DailyMed / ViiV Healthcare Company | Source revision: Source revision date not established in selected retrieval. CABENUVA intramuscular cabotegravir plus rilpivirine kit for eligible virologically suppressed HIV-1 patients; not PrEP.
Observed trial concentrations are not a validated therapeutic range
The neonatal source calls for concentration monitoring without a clearance-band regimen.
What to reconcile
Confirm citrate versus base expression and neonatal monitoring; no adult CrCl algorithm or invented target is supplied.
1 source identities and dates
GlobalRPh RX List - CAFCIT
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. CAFCIT caffeine citrate for apnea of prematurity; concentration-guided neonatal renal caution, not adult caffeine dosing.
A CKD indication is not permission to treat every renal stage
The selected RAYALDEE titration depends on stage and biochemical criteria, and excludes CKD stage 5 or dialysis.
What to reconcile
Keep calcium, phosphorus, PTH and vitamin D requirements attached; do not substitute calcitriol.
1 source identities and dates
GlobalRPh RX List - RAYALDEE
GlobalRPh-hosted RX List | Source revision: 1/2024 (printed mirror revision) RAYALDEE for adult secondary hyperparathyroidism with CKD stage 3 or 4 and low 25-hydroxyvitamin D; not calcitriol.
eviQ protocols disagree at the same indexed eGFR band
At eGFR 45-59 mL/min/1.73 m2, metastatic colorectal protocol 94 considers a 25% reduction or an alternative, whereas post-neoadjuvant breast protocol 3503 permits full dose with increased adverse-event risk. Protocol 94 explicitly identifies a committee-endorsed departure from ADDIKD.
What to reconcile
Choose by the exact cancer setting and protocol, not whichever dose is larger or smaller. These are two protocols from one organization, not independent confirmation. Record the indication, protocol number, renal metric and oncology rationale.
eviQ 3503 - post-neoadjuvant breast capecitabine renal guidance
eviQ / Cancer Institute NSW | Source revision: Source revision date not established in selected retrieval. eviQ protocol 3503, adult breast adjuvant capecitabine after neoadjuvant therapy.
The newly imported RX label specifies Cockcroft-Gault CrCl; the eviQ tables use indexed eGFR. Similar numbers do not establish equivalent renal categories. The newer RX text says a dose below CrCl 30 is not established, unlike the older preserved source restriction.
What to reconcile
Read the original and newer source in full. Do not convert a missing established dose into permission to use a regimen or substitute eGFR for CrCl without reconciling the method. A retrieval date alone does not establish a label version.
4 source identities and dates
Preserved original GlobalRPh material
GlobalRPh | Source revision: Not established Historical original source; not revalidated by this note.
GlobalRPh-hosted RX List | Source revision: December 2022 on retrieved RX page. Adult oral capecitabine; renal modification of the selected oncology regimen, not a complete chemotherapy protocol.
eviQ 3503 - post-neoadjuvant breast capecitabine renal guidance
eviQ / Cancer Institute NSW | Source revision: Source revision date not established in selected retrieval. eviQ protocol 3503, adult breast adjuvant capecitabine after neoadjuvant therapy.
Current label renal wording and DPYD testing need a dated reading
The retrieved 2026 official labels state that a dosage below Cockcroft-Gault CrCl 30 is not established, whereas the older generic RX mirror calls this range contraindicated. Current labels also include pretreatment DPYD testing precautions.
What to reconcile
Use the exact current product label and oncology protocol; do not interpret absence of an established dose as permission. Older eviQ comparisons were not rechecked in this pass.
3 source identities and dates
GlobalRPh RX List - capecitabine tablets
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Oral capecitabine: renal adjustment must be applied to the correct indication-specific regimen; DPYD/DPD and toxicity requirements remain separate.
Capecitabine tablets - Camber Pharmaceuticals, Inc.
DailyMed / Camber Pharmaceuticals, Inc. | Source revision: 1/2026 Oral capecitabine: renal adjustment must be applied to the correct indication-specific regimen; DPYD/DPD and toxicity requirements remain separate.
No adjustment in studied impairment is not protection from treatment-related renal injury
The source leaves severe impairment unstudied and separately warns about hyperglycemia, diarrhea and dehydration.
What to reconcile
Keep renal follow-up and treatment-related complications separate from baseline renal dosing.
1 source identities and dates
GlobalRPh RX List - TRUQAP
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. TRUQAP oral cancer therapy with its indicated partner regimen and intermittent schedule; renal findings alone do not establish treatment eligibility.
Keep Cockcroft-Gault and the unstudied severe range explicit
The no-adjustment finding is limited to the selected Cockcroft-Gault mild/moderate renal range.
What to reconcile
Do not convert an unstudied severe range into a dose or silently substitute indexed eGFR.
1 source identities and dates
GlobalRPh RX List - TABRECTA
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. TABRECTA oral targeted cancer therapy; indication, molecular eligibility and interaction adjustments remain separate.
The IV vehicle restriction must not be transferred to oral carbamazepine
The selected IV source warns about cyclodextrin accumulation and generally avoids moderate or severe renal impairment. Current availability was not verified.
What to reconcile
Match route and vehicle; do not invent severity cutoffs or a reduced IV schedule to bypass the restriction.
1 source identities and dates
GlobalRPh RX List - CARNEXIV
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. CARNEXIV IV carbamazepine temporary replacement formulation; not an oral carbamazepine renal rule. Current commercial availability was not verified.
Do not repair a damaged renal dose table by assumption
The mirror has missing separators in its BSA-based renal bands. Its separately legible Calvert relationship uses GFR and produces a total mg dose.
What to reconcile
Keep the malformed rows on hold. Confirm the oncology protocol, target exposure and renal-function method before using a dosing equation.
1 source identities and dates
GlobalRPh RX List - carboplatin IV
GlobalRPh-hosted RX List | Source revision: 3/2016 Carboplatin intravenous injection; oncology regimen and target exposure must be confirmed separately. No patient-specific calculation is supplied.
Only documented issues are searchable here. Absence of a note is not agreement. A label mirror and the original label are not independent corroboration, and a source's retrieval date is not its revision date.